ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a globa

Event · Earnings
Also in this documentGuidance · $48M–$52M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Aug 3, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CLPT
Bullish
medium confidence
Mentioned
$CLPT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLPTBullishMed
01

Why it matters

Traders can update models around (1) the revised 2026 revenue guidance range, (2) segment mix shift toward neurosurgery navigation/therapy, and (3) forward visibility tied to partner FDA feedback and expected trial enrollment/data readouts.

02

Market read

This is a primary results and guidance update with multiple near-to-mid-term catalysts, making it actionable for positioning around 2026 revenue expectations and commercialization readiness.

03

What to watch

The excerpt does not include cash balance, operating expenses, or detailed capex for CAL, which could materially affect valuation despite the revenue guidance range.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 3, 2026 with updated 2026 revenue guidance and Q2 results

Background

The 8-K (Item 2.02) contains ClearPoint Neuro’s Q2 2026 financial results and business outlook, including regulatory progress commentary and operational milestones (CAL possession, GLP statement of work, focused ultrasound partnership).

Company-level read

Ticker impact

$CLPTBullishMedium confidence
Context

ClearPoint Neuro reports Q2 2026 revenue of $10.9M and raises/adjusts 2026 revenue guidance to $48.0M-$52.0M amid CAL facility and focused ultrasound partnership updates.

Expected impact

Likely positive bias for CLPT as investors price higher 2026 revenue range and improved visibility into partner regulatory timelines and capacity buildout.

Evidence & confidence

The filing is a primary disclosure (8-K with results and outlook) and includes multiple concrete catalysts, but the excerpt does not provide margins, cash burn, or consensus comparisons, limiting precision on magnitude.

Market effects

Supports sentiment for neuro cell and gene therapy enabling platforms by highlighting partner FDA feedback and capacity expansion as a pathway to commercialization.

Limited direct regional read-through beyond global trial and regulatory execution themes.

Focused ultrasound partnership in South Korea and stated global footprint expansion may broaden perceived addressable market and execution optionality.

Counterpoint

Biologics and drug delivery revenue declined 15% in Q2, implying near-term demand timing risk even as the company expects a rebound in Q3.

Key entities

  • ClearPoint Neuro, Inc.

    Subject of the 8-K, reporting Q2 2026 results and revised 2026 revenue guidance, plus operational/regulatory milestones.

  • ClearPoint Advanced Laboratories (CAL)

    Preclinical lab facility in Torrey Pines now in company possession, with a first GLP statement of work expected to complete in H1 2027.

  • SONOCARE Lab at Sungkyunkwan University

    Partner for a 10-year focused ultrasound drug delivery initiative in South Korea.

  • FDA

    Company cites positive feedback to biopharma partners on potential BLA submissions and reversed guidance on rare disease decisions.

Related articles

$CLPTMed

ClearPoint Neuro (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) reported Q3 2026 revenue of $12.1M, up 36% YoY, driven by growth in neurosurgery navigation and capital equipment sales. The company used its ATM facility to raise $22M, ending the quarter with $46.2M in cash. CLPT supports uniQure's BLA submission for Huntington's disease treatment, aiming for parallel FDA approvals. The company is preparing for increased Phase III trials and commercial product launches in 2027.

$CLPTMed

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

ClearPoint Neuro (CLPT) reported Q3 operating expenses of $13.4M, down from $17M in Q2. Cash reserves were $46.2M, with $22M raised via equity offering. CEO Burnett expects reduced operating burn and capital expenditures. The company awaits FDA decision on AMT-130 submission, with potential parallel approvals for drug and device. ClearPoint outlined four growth pillars, including biologics, neurosurgery navigation, and laser therapy.

$CLPTMed

ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offerin